A Multidisciplinary Model Predicts Clinical Response in Relapsed Multiple Myeloma

被引：0
|
作者：
Shain, Kenneth H. [1 ]
Silva, Ariosto [2 ]
Meads, Mark B. [3 ]
Distler, Allison [3 ]
Jacobson, Timothy [2 ]
Gatenby, Robert [2 ]
Baz, Rachid [1 ]
Silva, Maria [4 ]
Rebatchouk, Dmitri [5 ]
Cubitt, Chris [4 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Intergrated Math Oncol, Tampa, FL USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] nPharmakon, Piscataway, NJ USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Clinical characteristics of patients with relapsed multiple myeloma
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Niesvizky, Ruben
    Palumbo, Antonio
    CANCER TREATMENT REVIEWS, 2015, 41 (10) : 827 - 835
  • [2] Clinical course of patients with relapsed multiple myeloma
    Kumar, SK
    Therneau, TM
    Gertz, MA
    Lacy, MQ
    Dispenzieri, A
    Rajkumar, SV
    Fonseca, R
    Witzig, TE
    Lust, JA
    Larson, DR
    Kyle, RA
    Greipp, PR
    MAYO CLINIC PROCEEDINGS, 2004, 79 (07) : 867 - 874
  • [3] In Vitro Model to Predict Response to Daratumumab Therapy in Relapsed/Refractory Multiple Myeloma
    Van Nieuwenhuijzen, Niels
    Cuenca, Marta
    Abbink, Leonie
    Lammers, Eline
    Jak, Margot
    Peperzak, Victor
    Minnema, Monique C.
    BLOOD, 2021, 138
  • [4] Response to Bortezomib in relapsed/refractory multiple myeloma serie
    Rubio-Martinez, A.
    Recasens, V.
    Montanes, M. A.
    Mayayo, P.
    Delgado, P.
    Garcia-Zueco, J. C.
    Rubio-Felix, D.
    Giraldo, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 165 - 166
  • [5] Effective response with bortezomib retreatment in relapsed multiple myeloma
    Taverna, Christian
    Voegeli, Jerome
    Trojan, Andreas
    Olie, Robert A.
    von Rohr, Albert
    SWISS MEDICAL WEEKLY, 2012, 142
  • [6] Response to bortezomib in relapsed/refractory multiple myeloma cohort
    Rubio-Martinez, A.
    Recasens, V.
    Montanes, M. A.
    Mayayo, P.
    Delgado, P.
    Garcia-Zueco, J. C.
    Rubio-Felix, D.
    Giraldo, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 472 - 472
  • [7] Durability of response with thalidomide therapy for relapsed multiple myeloma
    Myers, B
    Jones, SG
    Dolan, G
    7TH ANNUAL MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION, 2002, : 259 - 262
  • [8] TREATMENT RESPONSE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS
    Ioana, I.
    Liviu, C.
    Maria, C.
    Claudiu, I.
    Maria, I.
    Mihai, I.
    Dacian, O.
    Ovidiu, P.
    Cristina, S.
    Despina, C.
    Hortensia, I.
    HAEMATOLOGICA, 2013, 98 : 614 - 614
  • [9] Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient-derived in vitro model
    van Nieuwenhuijzen, Niels
    Cuenca, Marta
    Abbink, Leonie
    Jak, Margot
    Peperzak, Victor
    Minnema, Monique C.
    EJHAEM, 2024, 5 (01): : 141 - 146
  • [10] Developing a prediction model for response to lenalidomide treatment in refractory/relapsed multiple myeloma patients
    Chung, Y-J.
    Yim, S-H.
    Jung, S-H.
    ANNALS OF ONCOLOGY, 2017, 28
12345